This symposium provided an overview of the efficacy and safety of multikinase inhibitors in colorectal cancer, including treatment sequencing, followed…

Prof D’Amore opened the symposium by highlighting that management of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma…

The oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) sunitinib is a standard first-line therapy for patients with…

Oncologists face multiple challenges when treating patients with cancer, especially if patients are elderly or if they experience adverse events (AEs).

Paediatric cancer treatment has advanced significantly over the last half century to a point where >80% of all childhood cancer cases survive >5 years…

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML).

Endoscopic endonasal surgery has become a standard procedure for functional treatment of benign pathologies. Materials and improved surgeon skills have…

Breast cancer is one of the deadliest cancer types worldwide and consists of several subtypes differing in their molecular characteristics; each subtype…

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract, arising from the interstitial cells of…

Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. Allogeneic stem cell transplantation (alloSCT) is the therapeutic approach…